13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0002018299
Total reported value
$1.3B
$1.3B
45 檔
15.7%
According to the latest 13F quarterly dataset, Boxer Capital Management, LLC managed an equity portfolio of $1.3B at the end of Q4 2025, spanning 45 distinct U.S. exchange-listed positions.
In Q4 2025, Boxer Capital Management, LLC displayed an active expansion posture, initiating 15 new positions and adding to 14 existing holdings, outstripping position reductions.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | TNGX | Tango Therapeutics Inc | Stock-Other | 21.09% | -4.26% | +11.31% | |
| 2 | RVMD | Revolution Medicines Inc | Stock-Healthcare | 6.97% | +0.67% | — | |
| 3 | KOD | Kodiak Sciences Inc | Stock-Other | 6.95% | -2.47% | +51.47% | |
| 4 | KYMR | Kymera Therapeutics Inc | Stock-Other | 5.60% | +0.11% | +3.13% | |
| 5 | CELC | Celcuity Inc | Stock-Other | 4.91% | -0.09% | +150.00% | |
| 6 | ABVX | Abivax Sa-adr | Stock-Other | 3.69% | +3.15% | +4.17% | |
| 7 | PTCT | Ptc Therapeutics Inc | Stock-Healthcare | 3.33% | -0.56% | — | |
| 8 | 430 | Terns Pharmaceuticals Inc | Stock-Other | 3.32% | -2.60% | EXIT | |
| 9 | PTGX | Protagonist Therapeutics Inc | Stock-Other | 3.25% | -0.78% | +54.55% | |
| 10 | PRAX | Praxis Precision Medicines I | Stock-Other | 3.00% | -0.80% | — | |
| 11 | URGN | UroGen Pharma Ltd. | Stock-Other | 2.56% | +0.21% | -13.04% | |
| 12 | CDTX | Cidara Therapeutics Inc | Stock-Other | 2.56% | — | +10.42% | |
| 13 | PALI | Palisade Bio Inc | Stock-Other | 2.47% | -0.34% | — | |
| 14 | AMLX | Amylyx Pharmaceuticals Inc | Stock-Other | 2.12% | -0.38% | -11.11% | |
| 15 | SRZN | Surrozen Inc | Stock-Other | 2.06% | -0.90% | — | |
| 16 | CAPR | Capricor Therapeutics Inc | Stock-Other | 2.05% | +0.18% | — | |
| 17 | BRD1EUR | Mind Medicine Mindmed Inc | Stock-Other | 1.75% | — | +266.06% | |
| 18 | COGT | Cogent Biosciences Inc | Stock-Other | 1.75% | -0.48% | — | |
| 19 | REPL | Replimune Group Inc | Stock-Other | 1.60% | +2.14% | -28.57% | |
| 20 | QURE | uniQure N.V. | Stock-Other | 1.52% | +3.79% | -63.75% | |
| 21 | CYTK | Cytokinetics Inc | Stock-Healthcare | 1.39% | -0.23% | -50.00% | |
| 22 | HELP | Cybin Inc | Stock-Other | 1.28% | -0.01% | — | |
| 23 | PGEN | Precigen Inc | Stock-Other | 1.26% | +0.43% | +61.76% | |
| 24 | CTNM | Contineum Therapeutics Inc-a | Stock-Other | 1.24% | -0.24% | — | |
| 25 | ✓ | Crescent Biopharma Inc. | Stock-Other | 1.18% | — | — | |
| 26 | APGE | Apogee Therapeutics Inc | Stock-Other | 1.16% | -0.07% | +40.00% | |
| 27 | GPCR | Structure Therapeutics Inc | Stock-Other | 1.14% | -0.17% | — | |
| 28 | AVTX | Avalo Therapeutics Inc | Stock-Other | 1.09% | -0.07% | +120.00% | |
| 29 | INO | Inovio Pharmaceuticals Inc | Stock-Other | 0.92% | -0.30% | +5.22% | |
| 30 | UPB | Upstream Bio Inc | Stock-Other | 0.89% | -0.10% | — | |
| 31 | VIR | Vir Biotechnology Inc | Stock-Other | 0.82% | -0.77% | — | |
| 32 | IVVD | Invivyd Inc | Stock-Other | 0.81% | -0.16% | — | |
| 33 | MLTX | Moonlake Immunotherapeutics | Stock-Other | 0.79% | -0.27% | +10.00% | |
| 34 | SRPT | Sarepta Therapeutics Inc | Stock-Healthcare | 0.71% | -0.23% | -40.00% | |
| 35 | PEPG | Pepgen Inc | Stock-Other | 0.53% | -0.02% | +49.56% | |
| 36 | NRIX | Nurix Therapeutics Inc | Stock-Other | 0.42% | -0.02% | -42.86% | |
| 37 | KPTI | Karyopharm Therapeutics Inc | Stock-Other | 0.41% | — | — | |
| 38 | SLDB | Solid Biosciences Inc | Stock-Other | 0.37% | -0.05% | -50.00% | |
| 39 | LBRX | Lb Pharmaceuticals Inc | Stock-Other | 0.34% | -0.06% | — | |
| 40 | MIST | Milestone Pharmaceuticals In | Stock-Other | 0.29% | -0.03% | — | |
| 41 | CLNN | Clene Inc | Stock-Other | 0.26% | -0.09% | — | |
| 42 | 4XC1 | Kalvista Pharmaceuticals Inc | Stock-Other | 0.07% | -0.05% | EXIT | |
| 43 | ✓ | Zura Bio LTD | Stock-Other | 0.06% | -0.30% | — | |
| 44 | NUVB-WS | Nuvation Bio Inc -cw27 | Stock-Other | 0.02% | — | — | |
| 45 | SRZNW | Surrozen Inc-cw25 | Stock-Other | — | — | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | CELC | Celcuity Inc | +3.5% | +150.00% | Add |
| 2 | KOD | Kodiak Sciences Inc | +3% | +51.47% | Add |
| 3 | BRD1EUR | Mind Medicine Mindmed Inc | +1.1% | +266.06% | Add |
| 4 | CDTX | Cidara Therapeutics Inc | +1.1% | +10.42% | Add |
| 5 | RVMD | Revolution Medicines Inc | +1% | — | Unchanged |
| 6 | PTGX | Protagonist Therapeutics Inc | +0.9% | +54.55% | Add |
| 7 | AVTX | Avalo Therapeutics Inc | +0.6% | +120.00% | Add |
| 8 | APGE | Apogee Therapeutics Inc | +0.5% | +40.00% | Add |
| 9 | ABVX | Abivax Sa-adr | +0.4% | +4.17% | Add |
| 10 | PGEN | Precigen Inc | +0.4% | +61.76% | Add |
| 11 | MLTX | Moonlake Immunotherapeutics | +0.2% | +10.00% | Add |
| 12 | REPL | Replimune Group Inc | +0.2% | -28.57% | Trim |
| 13 | PEPG | Pepgen Inc | +0.2% | +49.56% | Add |
| 14 | NUVB-WS | Nuvation Bio Inc -cw27 | — | — | Unchanged |
| 15 | SRZNW | Surrozen Inc-cw25 | — | — | Unchanged |
| 16 | LBRX | Lb Pharmaceuticals Inc | 0% | — | Unchanged |
| 17 | 4XC1 | Kalvista Pharmaceuticals Inc | 0% | — | Unchanged |
| 18 | NRIX | Nurix Therapeutics Inc | -0.1% | -42.86% | Trim |
| 19 | MIST | Milestone Pharmaceuticals In | -0.1% | — | Unchanged |
| 20 | KYMR | Kymera Therapeutics Inc | -0.2% | +3.13% | Add |
| 21 | ✓ | Crescent Biopharma Inc. | -0.5% | — | Unchanged |
| 22 | PTCT | Ptc Therapeutics Inc | -0.6% | — | Unchanged |
| 23 | INO | Inovio Pharmaceuticals Inc | -0.8% | +5.22% | Add |
| 24 | SLDB | Solid Biosciences Inc | -0.8% | -50.00% | Trim |
| 25 | SRPT | Sarepta Therapeutics Inc | -0.8% | -40.00% | Trim |
| 26 | URGN | UroGen Pharma Ltd. | -1.1% | -13.04% | Trim |
| 27 | AMLX | Amylyx Pharmaceuticals Inc | -1.8% | -11.11% | Trim |
| 28 | CYTK | Cytokinetics Inc | -2.1% | -50.00% | Trim |
| 29 | TNGX | Tango Therapeutics Inc | -5.1% | +11.31% | Add |
| 30 | QURE | uniQure N.V. | -13.4% | -63.75% | Trim |
| 31 | 430 | Terns Pharmaceuticals Inc | — | NEW | New buy |
| 32 | PRAX | Praxis Precision Medicines I | — | NEW | New buy |
| 33 | ✓ | Merus N V | — | EXIT | Sold out |
| 34 | PALI | Palisade Bio Inc | — | NEW | New buy |
| 35 | SRZN | Surrozen Inc | — | NEW | New buy |
| 36 | CAPR | Capricor Therapeutics Inc | — | NEW | New buy |
| 37 | COGT | Cogent Biosciences Inc | — | NEW | New buy |
| 38 | NKTR | Nektar Therapeutics | — | EXIT | Sold out |
| 39 | HELP | Cybin Inc | — | NEW | New buy |
| 40 | CTNM | Contineum Therapeutics Inc-a | — | NEW | New buy |
| 41 | GPCR | Structure Therapeutics Inc | — | NEW | New buy |
| 42 | UPB | Upstream Bio Inc | — | NEW | New buy |
| 43 | VIR | Vir Biotechnology Inc | — | NEW | New buy |
| 44 | IVVD | Invivyd Inc | — | NEW | New buy |
| 45 | DNLI | Denali Therapeutics Inc | — | EXIT | Sold out |
| 46 | KPTI | Karyopharm Therapeutics Inc | — | NEW | New buy |
| 47 | CLNN | Clene Inc | — | NEW | New buy |
| 48 | TIL | Instil Bio Inc | — | EXIT | Sold out |
| 49 | ✓ | Zura Bio LTD | — | NEW | New buy |
According to official SEC Form 13F filings, Boxer Capital Management, LLC reported a total U.S. public equity portfolio value of $1.3B across 45 disclosed positions in Q4 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including TNGX, RVMD, KOD) accounted for 15.7% of total reported equity market value during Q4 2025.
Top New Position Initiated
430
市值: $15.2M
Top Position Liquidated / Trimmed
MERUS N V
前期市值: $11.3M
During Q4 2025, Boxer Capital Management, LLC's top holdings by market value included TNGX (21.1%)、RVMD (7.0%)、KOD (7.0%). The largest single position, TNGX, represented 21.1% of total portfolio value.
In Q4 2025, Boxer Capital Management, LLC made 41 total portfolio adjustments, initiating 15 new buys, adding to 14 positions, trimming 8 holdings, and fully liquidating 4 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.